Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to 405.3%.

  • Stoke Therapeutics' EBIT Margin rose 2077600.0% to 405.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.23%, marking a year-over-year increase of 7138300.0%. This contributed to the annual value of 277.31% for FY2024, which is 10299000.0% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' EBIT Margin is 405.3%, which was up 2077600.0% from 197.58% recorded in Q2 2025.
  • Stoke Therapeutics' EBIT Margin's 5-year high stood at 70.15% during Q1 2025, with a 5-year trough of 1340.67% in Q2 2023.
  • Its 4-year average for EBIT Margin is 637.29%, with a median of 672.96% in 2024.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -5595500bps in 2023, then skyrocketed by 9955100bps in 2024.
  • Over the past 4 years, Stoke Therapeutics' EBIT Margin (Quarter) stood at 831.58% in 2022, then dropped by -27bps to 1055.89% in 2023, then surged by 94bps to 60.37% in 2024, then plummeted by -571bps to 405.3% in 2025.
  • Its EBIT Margin was 405.3% in Q3 2025, compared to 197.58% in Q2 2025 and 70.15% in Q1 2025.